Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Univec, Inc. (UNVC)
Owings Mills, MD, US
Univec, Inc. is a medical device firm that, through its various operating divisions, develops, licenses, and sells products across the United States and internationally. Its primary offerings include a range of auto-disable and safety syringes. These encompass 1cc AD-syringes, which can be used for both aspirating and non-aspirating procedures, typically for dispensing precise doses of allergy, immunization, and insulin medications. Univec also produces sliding sheath syringes, engineered to protect both patients and healthcare professionals from accidental needlestick injuries. Additionally, the company manufactures bifurcated needle safety syringes, specifically designed for administering smallpox vaccines, particularly in response to potential bioterrorist threats. Univec distributes its auto-disable and sliding sheath safety syringes to private hospitals, other healthcare facilities, and distributors within the U.S., as well as to governmental entities in developing countries. Furthermore, it offers an online system that assists pharmaceutical companies with the marketing, fulfillment, and tracking of drug samples, serving as a connector between pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+131.0% ★ Q4'25: +23.6% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+200.0% ★ Q4'25: +200.0% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-18,292.6% Q4'25: -88,687.1% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1,415.2% Q4'25: -2,005.4% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q4'25: +8.6% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.21× Q4'25: -1.03× (vs Q4'24)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2004 | Dr.David Dalton, Chief Executive and President | 396.0K | — | — | — | — | — | 396.0K | 0.00% | ↗ |
| 2 | 2003 | Dr.David Dalton, Chief Executive and President | 360.0K | — | — | 1.00M | — | — | 1.36M | 73.53% | ↗ |
| 3 | 2003 | Joel Schoenfeld, Chairman | — | — | — | 500.0K | — | — | 500.0K | 100.00% | ↗ |
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Dalton | CEO, President & Director | 39.9K | — |
| Raphael Langford | Chief Operating Officer and Executive Vice President | 13.3K | male |
| Michael A. Lesisko | Chief Financial Officer, Secretary and Treasurer | 12.5K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UNVC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
